Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: A post hoc, pooled analysis from two placebo-controlled trials

Neurourology and Urodynamics

Volumn 31, Issue 8, 2012, Pages 1258-1265

  Dubeau, Catherine E ^a   Morrow, Jon D ^b   Kraus, Stephen R ^c   Creanga, Dana ^d   Bavendam, Tamara ^d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d PFIZER INC   (United States)

Author keywords

antimuscarinic agents; fesoterodine; older persons; overactive bladder; patient reported outcomes; quality of life; randomized controlled trials; signs and symptoms; tolterodine

Indexed keywords

FESOTERODINE; PLACEBO; TOLTERODINE;

ADULT; ADVERSE OUTCOME; AGE; AGED; ARTICLE; BLURRED VISION; COMPARATIVE STUDY; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; POST HOC ANALYSIS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URGE INCONTINENCE; URINE INCONTINENCE; URINE VOLUME; XEROSTOMIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CRESOLS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE; URINATION; YOUNG ADULT;

EID: 84867889726     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22252     Document Type: Article

References (29)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78.
2. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010; 29: 4-20.
3. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306-15.
4. Irwin DE, Milsom I, Chancellor MB, et al. Dynamic progression of overactive bladder and urinary incontinence symptoms: A systematic review. Eur Urol 2010; 58: 532-43.
5. Malmsten UG, Molander U, Peeker R, et al. Urinary incontinence, overactive bladder, and other lower urinary tract symptoms: A longitudinal population-based survey in men aged 45-103 years. Eur Urol 2010; 58: 149-56.
6. Wennberg AL, Molander U, Fall M, et al. Lower urinary tract symptoms: Lack of change in prevalence and help-seeking behaviour in two population-based surveys of women in 1991 and 2007. BJU Int 2009; 104: 954-9.
7. Brown JS, Vittinghoff E, Wyman JF, et al. Urinary incontinence: Does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 2000; 48: 721-5.
8. DuBeau CE, Levy B, Mangione CM, et al. The impact of urge urinary incontinence on quality of life: Importance of patients' perspective and explanatory style. J Am Geriatr Soc 1998; 46: 683-92.
9. DuBeau C, Kuchel GA, Johnson T, et al. Incontinence in the frail elderly. In:, Abrams P, Cardozo L, Khoury S, Wein A, editors. Incontinence, 4th edition. Paris: Editions 21, for Health Publication Ltd; 2009. 963-1024.
10. Kraus SR, Bavendam T, Brake T, et al. Vulnerable elderly patients and overactive bladder syndrome. Drugs Aging 2010; 27: 697-713.
11. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2003; 163: 2716-24.
12. Malone-Lee JG, Walsh JB, Maugourd MF,. Tolterodine: A safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001; 49: 700-5.
13. Zinner NR, Mattiasson A, Stanton SL,. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002; 50: 799-807.
14. Chapple C, DuBeau C, Ebinger U, et al. Darifenacin treatment of patients >or= 65 years with overactive bladder: Results of a randomized, controlled, 12-week trial. Curr Med Res Opin 2007; 23: 2347-58.
15. Wagg A, Wyndaele JJ, Sieber P,. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysis. Am J Geriatr Pharmacother 2006; 4: 14-24.
16. Kraus SR, Ruiz-Cerdá JL, Martire D, et al. Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. Urology 2010; 76: 1350-7.
17. Michel MC, Schneider T, Krege S, et al. Does gender or age affect the efficacy and safety of tolterodine ? J Urol 2002; 168: 1027-31.
18. Foote J, Glavind K, Kralidis G, et al. Treatment of overactive bladder in the older patient: Pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist. Eur Urol 2005; 48: 471-7.
19. Griebling TL, Kraus SR, Richter HE, et al. Tolterodine extended release is well tolerated in older subjects. Int J Clin Pract 2009; 63: 1198-204.
20. Michel MC,. Fesoterodine: A novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 1787-96.
21. Malhotra BK, Wood N, Sachse R,. Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. Int J Clin Pharmacol Ther 2009; 47: 570-8.
22. Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52: 1204-12.
23. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol 2007; 178: 2488-94.
24. Herschorn S, Swift S, Guan Z, et al. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: A head-to-head placebo-controlled trial. BJU Int 2010; 105: 58-66.
25. Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: A prospective, head-to-head, placebo-controlled trial. BJU Int 2011; 107: 1432-40.
26. Brockett PL, Levine A,. On a characterization of ridits. Ann Stat 1977; 5: 1245-8.
27. Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
28. Kaplan SA, Wein AJ, Staskin DR, et al. Urinary retention and post-void residual urine in men: Separating truth from tradition. J Urol 2008; 180: 47-54.
29. Kaplan SA, Roehrborn CG, Abrams P,. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: A systematic review. Int J Clin Pract 2011; 65: 487-507.